These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29124399)

  • 1. Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.
    Les I; Parraza N; Anaut P; Eguiluz S; Sánchez C; Preciado ME; Loza JÁ; Andía A
    Rheumatol Int; 2018 Feb; 38(2):229-238. PubMed ID: 29124399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity.
    Yelnik CM; Urbanski G; Drumez E; Sobanski V; Maillard H; Lanteri A; Morell-Dubois S; Caron C; Dubucquoi S; Launay D; Duhamel A; Hachulla E; Hatron PY; Lambert M
    Lupus; 2017 Feb; 26(2):163-169. PubMed ID: 27432808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
    Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
    Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria.
    Demetrio Pablo R; Muñoz P; López-Hoyos M; Calvo V; Riancho L; Martínez-Taboada VM
    Med Clin (Barc); 2017 May; 148(9):394-400. PubMed ID: 28153433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study).
    Bazzan M; Vaccarino A; Stella S; Sciascia S; Montaruli B; Bertero MT; Carignola R; Roccatello D;
    Lupus; 2016 Apr; 25(5):479-85. PubMed ID: 26657216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.
    Hisada R; Kato M; Sugawara E; Fujieda Y; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
    J Thromb Haemost; 2017 Sep; 15(9):1782-1787. PubMed ID: 28662299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
    Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
    Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers.
    Sloan E; Wright T; Zuo Y
    Lupus; 2021 Apr; 30(5):828-832. PubMed ID: 33736541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.
    Otomo K; Atsumi T; Amengual O; Fujieda Y; Kato M; Oku K; Horita T; Yasuda S; Koike T
    Arthritis Rheum; 2012 Feb; 64(2):504-12. PubMed ID: 21953404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiphospholipid antibodies: evaluation of the thrombotic risk.
    Devreese KM
    Thromb Res; 2012 Oct; 130 Suppl 1():S37-40. PubMed ID: 23026657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus.
    Martínez-Berriotxoa A; Ruiz-Irastorza G; Egurbide MV; Rueda M; Aguirre C
    Lupus; 2004; 13(12):927-33. PubMed ID: 15645748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies.
    Kim KJ; Baek IW; Yoon CH; Kim WU; Cho CS
    Br J Haematol; 2013 Jun; 161(5):706-714. PubMed ID: 23530551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.
    Chen J; Sun S; Yan Q; Bao C; Fu Q
    Clin Rheumatol; 2016 Feb; 35(2):333-40. PubMed ID: 26753544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity.
    Pyo JY; Jung SM; Lee SW; Song JJ; Lee SK; Park YB
    Yonsei Med J; 2017 Nov; 58(6):1128-1134. PubMed ID: 29047236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the detection of antibodies directed against domain 1 of β2-glycoprotein 1 in thrombotic antiphospholipid syndrome.
    Montalvão S; Elídio PS; da Silva Saraiva S; de Moraes Mazetto B; Colella MP; de Paula EV; Appenzeller S; Annichino-Bizzacchi J; Orsi FA
    Thromb Res; 2016 Dec; 148():32-37. PubMed ID: 27770664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis.
    Kassis J; Neville C; Rauch J; Busque L; Chang ER; Joseph L; Le Comte M; Subang R; Fortin PR
    Thromb Haemost; 2004 Dec; 92(6):1312-9. PubMed ID: 15583739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiphospholipid antibodies in neonates with stroke--a unique entity or variant of antiphospholipid syndrome?
    Berkun Y; Simchen MJ; Strauss T; Menashcu S; Padeh S; Kenet G
    Lupus; 2014 Sep; 23(10):986-93. PubMed ID: 24729280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.